From the initial discovery of the recurring chromosomal translocation encoding chimaeric PML--retinoic acid receptor alpha (RARalpha) fusion to the successful application of *all-trans* retinoic acid (ATRA) treatment for induction of complete remission, acute promyelocytic leukaemia (APL), which accounts for ∼10% of all cases of acute myeloid leukaemias (AMLs), has become the paradigm of differentiation therapy and one of the most successfully targeted cancers. ATRA plus anthracycline-based chemotherapy that has been the standard regimen for APL therapy in the last decades can achieve long-term remissions close to 80% ([@bib41]). The revolutionary development of ATRA was closely followed by another major discovery of arsenic trioxide (ATO) treatment that has markedly improved the management of relapsed and refractory APL patients, and now rapidly enters therapy regimens for newly diagnosed low-to-intermediate-risk APL patients in combination with ATRA ([@bib6]; [@bib30]). ATRA/ATO with reduced haematological toxicity compared with anthracycline-based regimens is likely to further improve long-term outcomes for APL patients ([@bib45]; [@bib56]). Thus, hope is arising that chemotherapy in APL may become largely dispensable and be solely replaced by targeted therapeutic approaches. In spite of these successes, the role of ATRA/ATO for high-risk patients has not yet been clarified. Also relapsed and refractory APL patients, due to ATRA and/or ATO resistance, still occur among all prognostic subgroups of APL patients, and remain a clinically significant problem in the field ([@bib19]; [@bib17]; [@bib53]). An improved understanding of the mechanisms underlying the oncogenic transformation and treatment response in APL is urgently needed for development of better therapeutic strategies. In this article, we will review the molecular basis, in particular, the transcriptional and epigenetic machineries that are critically involved in APL development, as well as their roles in mediating response and resistance to ATRA treatments. Although the epigenetic regulation has a key role in mediating ATRA response/resistance, it is unlikely the only answer to all APL therapies such as ATO treatment. Since the role of ATRA/ATO-mediated onco-fusion degradation in disease remission has been extensively reviewed elsewhere ([@bib1]; [@bib25]), the current review will mainly focus on the epigenetic aspects, and its potential future development in APL treatment.

Epigenetic in APL
=================

Although transcriptional deregulation has a central role in a large array of cancers including acute leukaemia, it is evident that epigenetic machineries including DNA methylation and post-translational histone modifications constitute integral functions of the oncogenic transcriptional complexes in mediating the aberrant transcriptional programmes ([@bib9]). Consistently, we and others have revealed that RARalpha fusions form high-order homotetramers ([@bib27]; [@bib35]; [@bib24]; [@bib49]) that aberrantly recruit the DNA-binding cofactor, RXRalpha ([@bib58]; [@bib61]), as well as epigenetic-modifying enzymes such as histone deacetylases (HDACs) ([@bib20]; [@bib28]), DNA methyltransferases (DNMTs) ([@bib12]), SUV39H1 ([@bib7]), and polycomb repressive complexes (PRCs) 1 and 2 ([@bib54]; [@bib5]; [@bib46]) to suppress expression of downstream targets critical for differentiation and tumour suppression ([Figure 1A](#fig1){ref-type="fig"}).

On the other hand, epigenetic mechanisms driving APL leukaemogenesis also include the emerging new epigenetic factor, miRNAs (micro RNAs) such as Let-7c ([@bib42]), which is upregulated to promote granulocytic differentiation of APL cells in part by suppressing PBX2 upon ATRA treatment ([@bib36]; [Figure 1B](#fig1){ref-type="fig"}). miRNA-223 regulated by C/EBPalpha and NFI-A is also activated upon ATRA for granulocytic differentiation of APL cells ([@bib13]; [Figure 1B](#fig1){ref-type="fig"}). In addition, upregulation of miRNA-125b has been shown to contribute to paediatric APL and is associated with increased drug resistance ([@bib60]). Although abnormal expression of miRNAs in APL may provide extended diagnostic options and potential targets for molecular therapy, development of the pharmacological mean for targeting specific miRNAs is still in an early experimental stage. At the same time, the highly tractable epigenetic-modifying enzymes that are critical for pathogenesis and treatment response will likely present potential targets for the next wave of targeted therapies.

DNA methylation in APL
======================

DNA methylation is a well-characterised epigenetic process regulated by DNMTs that transfer methyl groups to cytosine in cytosine--guanine dinucleotide (CpG) islands commonly found in promoter regions. DNA methylation stably regulates cellular gene expression and mostly associates with gene suppression. Given its critical functions in gene regulation, it is not surprising that DNA methylation has a crucial role in the development of various cancers including AML ([@bib3]; [@bib43]). The first hint of DNA methylation involvement in APL came from the studies by [@bib12], who demonstrated that PML--RARalpha directly interacted with DNMTs (e.g., DNMT1 and DNMT3a) leading to hypermethylation and subsequent silencing of downstream targets, such as *RARbeta* crucial for haematopoietic differentiation ([Figure 1A](#fig1){ref-type="fig"}). Consistently, APL patients are characterised by a specific DNA methylation pattern that is distinctive from other AML subtypes ([@bib15]). More importantly, overexpression of the DNMT3a collaborates with PML--RARalpha to promote APL leukaemogenesis *in vivo* ([@bib50]), and aberrant DNA methylation in *p15* and *p16* genes has negative prognostic impact in APL patients ([@bib10]; [@bib52]), suggesting a critical role of aberrant DNA methylation in APL pathogenesis.

However, recent global epigenetic analyses revealed that ATRA treatment induced major changes in post-translational modifications such as histone acetylation, but not DNA methylation in APL cells ([@bib32]; [@bib34]). Although DNA hypermethylation in APL cells occurred frequently at genomic regions regulated by PRC2, such as SUZ12- and REST-binding sites in embryonic stem cells ([@bib44]), no major difference in the DNA methylation signature at PML--RARalpha DNA-binding sites or its vicinities was found in comparison with controls ([@bib32]; [@bib55]; [@bib44]). These studies suggest that the change of DNA methylation patterns may be relatively late events in APL leukaemogenesis, and contribute to APL maintenance rather than to leukaemia initiation ([@bib44]). Nevertheless, the DNA demethylating agent decitabine can induce apoptosis of APL cells *in vitro* via activation of the TRAIL pathway ([@bib47]). Thus, although it may mainly target the late collaborative events, reversal of the aberrant DNA methylation status appears to be an attractive therapeutic approach, in particular, when combined with ATRA/ATO for APL treatment.

A key role of histone acetylation in APL pathogenesis and ATRA response
=======================================================================

Compared with DNA methylation, aberrant DNA binding and histone modifications including acetylation and methylation may have had even more important roles in APL pathogenesis and treatment response. Global epigenetic studies have shown that, although wild-type RARalpha binding is mostly restricted to canonical retinoic acid response element (RARE)-binding sites, around 30% of the PML--RARalpha-binding sites are atypical RARE motifs ([@bib32]; [@bib55]), which are probably attributed by the homo/hetero-oligomeric nature of the fusions ([@bib58]; [@bib61]). More importantly, these studies also revealed that the vast majority of PML--RARalpha-binding sites, associated with distinct histone modifications characterised by low H3-acetylation (H3ac), reduced H3K27 trimethylation (H3K27me3) and increased H3K9me3 ([@bib22]; [@bib32]). Strikingly, ATRA treatment induced a significant increase of H3ac in about 80% of the PML--RARalpha-binding sites, including genes that are crucial for haematopoietic differentiation ([Figure 1B](#fig1){ref-type="fig"}). On contrast, H3K27me3 and H3K9me3 levels remained largely unchanged ([@bib32]). CpG DNA methylation, which has been shown to crosstalk with H3K27me3, also did not show significant changes upon ATRA treatment either. Although these studies suggest histone acetylation rather than H3K27me3 to be critical for ATRA response in APL, it is noted that a small number of PML--RARalpha-binding sites do correlate with the changes of H3K27me3 and DNA methylation upon ATRA treatment ([@bib32]). Future functional validation is needed to further investigate the importance of these changes and to define the major epigenetic determinants for the ATRA treatment response ([@bib34]).

The role of histone modification in APL pathogenesis is also highlighted by the study of a variant APL fusion, PLZF--RARalpha, which has a higher binding ability to SMRT/NcoR/HDAC ([@bib20]; [@bib28]), and is in general more resistant to ATRA treatment ([@bib59]). Interestingly, although recent genome-wide studies revealed overlapping targets by PLZF--RARalpha and PML--RARalpha ([@bib39]; [@bib48]), PLZF--RARalpha significantly increased H3K27me3 and concomitantly decreased H3K9K14ac at targeted sites ([@bib48]). Thus, different histone codes may account for the differences in ATRA response, and can potentially be exploited to improve treatment response.

Histone demethylase PHF8 as a crucial co-activator governing ATRA response
==========================================================================

Although the aberrant recruitment of transcriptional co-repressor complexes by RARalpha is critical for APL pathogenesis, it becomes evident that the recruitment of opposing activator complexes upon ATRA treatment has a central role in mediating treatment response ([@bib34]). Identification of these missing ATRA-responsive co-activators may hold a key to improve not only our understanding of the biology of the disease, but also development of more effective therapeutic strategies. Very recently, a histone demethylase and a member of the plant homeodomain finger (PHF) family, PHF8 has been identified as a key co-activator specially recruited by RARalpha fusions to mediate ATRA response in APL ([@bib2]). PHF8 contains a N-terminal plant homeodomain as well as an active JmjC domain, which is able to recognise H3K4me3 mark and mediates lysine demethylation, respectively ([@bib14]; [@bib16]; [@bib23]; [@bib29]; [@bib31]; [@bib38]). In the presence of ATRA, PHF8 is specifically recruited by RARalpha fusions to activate expression of their downstream target genes ([@bib2]). Recruitment of PHF8 leads to a reduction of the H3K9me2-repressive mark and an increase in the H3K4me3 and H3K9Ac activation marks for active gene expression ([Figure 1B](#fig1){ref-type="fig"}). Consistently, PHF8 expression is downregulated in ATRA-resistant human APL cells. Forced expression of PHF8 resurrects ATRA sensitivity, whereas its suppression leads to resistance ([@bib2]). PHF8 binds to promoter regions of genes involved in cell cycle progression and dissociates from these promoters upon phosphorylation of S33/S84 residues by CDK1 ([@bib29]; [Figure 1A](#fig1){ref-type="fig"}). ATRA can induce nuclear translocation of CDK1 that promotes PHF8 phosphorylation and binding to the promoter regions of RARalpha-fusion target genes for epigenetic reprogramming ([@bib2]). Consistently, expression of hyperphosphorylated PHF8 alone can activate expression of PML--RARalpha downstream targets and suppress transformation of ATRA-resistant APL cells ([Figure 1B](#fig1){ref-type="fig"}). Together, these studies reveal PHF8 as a key molecular sensor that governs ATRA response in APL. More importantly, these functions of PHF8 critically depend on both its enzymatic activity and phosphorylation status, which can potentially be therapeutically exploited ([@bib2]).

Targeting epigenetic machinery to overcome ATRA resistance in APL
=================================================================

Resistance to ATRA still occurs in a proportion of APL patients and remains a clinically significant problem in APL therapy ([@bib17]) Thus, uncovering the underlying mechanisms and designing specific therapeutic strategies to overcome ATRA resistance is of a high priority in the field. Point mutations within the PML--RARalpha ligand-binding domain (LBD) have been found and account for ∼40% of ATRA-resistant APL ([@bib18]). Given the central role of epigenetic reprogramming underlying ATRA response, another major resistant mechanism, which may also apply to the variant PLZF--RARalpha fusion, is due to the formation of aberrant repression complexes that cannot be easily dissociated by ATRA treatment ([@bib33]).

To improve the potency of ATRA response, a significant amount of effort has been made to develop synthetic retinoids with a higher RARalpha-binding affinity ([Figure 2](#fig2){ref-type="fig"}). However, most of the derivatives were not able to definitively overcome ATRA resistance or were associated with significant toxicity to the patients ([@bib37]). As recruitment of HDACs by RARalpha fusions has a major role in oncogenic transformation in APL, the idea of using HDAC inhibitors (HDACi) to overcome ATRA resistance has gained significant attention in the past few years ([Figure 2](#fig2){ref-type="fig"}). In fact, re-sensitization of ATRA-resistant APL cells can be achieved by HDACi ([@bib21]; [@bib37]; [@bib4]). Valproic acid (VPA) alone has been shown to induce differentiation of APL blasts and transient remission in mouse models ([@bib26]). In spite of these, HDACi seem to be effective only for a small subset of ATRA-resistant PML--RARalpha mutants carrying mutations affecting helix 12, but not helix 5/6 of the LBD in the fusion ([@bib11]), and may upregulate multidrug resistance 1 (*MDR1*) gene expression resulting in drug resistance ([@bib51]). Moreover, HDACs can have a dual tumour suppressor and oncogenic role, depending on the stage of the disease. Although suppression of HDAC1 prolonged disease latency in APL mouse models, inhibition of HDAC1 (and HDAC2) would accelerate APL pathogenesis in the early transformation stage owing to its effect on the expansion of a subset of APL cells with leukaemia-initiating features ([@bib40]). In fact, VPA treatment in an APL mouse model failed to target leukaemia-initiating cells and only resulted in transient responses ([@bib26]). Thus, overcoming these limitations is required to fully exploit the therapeutic potentials of HDACi in APL therapy in the future.

The recent discovery of PHF8 as a molecular sensor that regulates ATRA response in APL has suggested a novel avenue for overcoming ATRA resistance ([Figure 2](#fig2){ref-type="fig"}). PHF8 is capable of resurrecting ATRA sensitivity in resistant APL cells. The critical regulation of PHF8 activity by specific phosphorylation has provided an alternative pharmacological approach for overcoming ATRA resistance in APL cells. Indeed, inhibition of PHF8 dephosphorylation by the phosphatase inhibitor Okadaic acid has been shown to sensitise ATRA-resistant human APL cells to the treatment *in vitro* and *in vivo,* resulting in a significant extension of disease latency in xenograft models ([@bib2]). Moreover, PHF8 exhibits a broad range of *in vitro* and *in vivo* activities against ATRA resistance due to LBD mutations or formation of aberrant transcriptional repression complexes. In contrast to ATRA resistance, ATO resistance associates with mutations affecting the PML moiety that disrupt ATO-mediated degradation of the onco-fusion ([@bib19]). Given the nature of PHF8 binding to the RARalpha moiety of the fusions, it is tempting to speculate its potential usefulness in overcoming ATO resistance (Fung and So, 2013). Thus, future identification of specific phosphatases inhibitors or the pharmacological activator of PHF8 may represent an alternative avenue for targeting treatment resistance in APL.

Outlook
=======

ATRA- and ATO-containing regimens have significantly improved the overall and disease-free survival of *de novo* and relapsed APL patients ([Figure 2](#fig2){ref-type="fig"}). The recent results of a phase III clinical trial using ATRA plus ATO as the first-line therapy for low-to-intermediate-risk APL patients show improved 2 years disease-free and overall survival with a significant reduction of haematologic toxicity and lower rates of infections, revealing the promise of curing APL patients without administration of chemotherapy ([@bib8]; [@bib30]). However, their role in high-risk patients has yet to be determined. Other challenging issues, such as the reduction of early haemorrhagic death rate in APL therapy still remains. Also, some patients, especially those \>60 years of age are not eligible for aggressive therapy regimens, and for younger patients, late toxicity of chemotherapy can induce serious complications. Finally, relapsed and refractory APL patients due to ATRA and/or ATO resistance can be a major challenge for these targeted APL therapies ([@bib17]). While it becomes clear that the largely reversible nature of epigenetic modifications provides an unprecedented opportunity to target oncogenic transcription factors frequently mutated in acute leukaemia ([@bib9]; [@bib57]), ongoing and future studies in dissecting and targeting tractable epigenetic modifying enzymes critical for pathogenesis will likely represent the next wave of successful targeted cancer therapies.
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![**Epigenetic functions of PML--RARalpha in APL pathogenesis and treatment response.** (**A**) In APL cells, homotetrameric PML--RARalpha (for simplicity, the homotetramer is not illustrated in the figure) recruits multiple repressive epigenetic modifiers including DNMTs (green), PRC complexes (yellow), lysine methyltransferases (blue), and the histone lysine deactylase complex (pink). In the absence of ATRA, PHF8 is hypo-phosphorylated and associates with transcription factors (TFs) to binds to different chromatin regions (naive promoters). (**B**) Upon ATRA treatment, ATRA (red triangle) binds to RARalpha moiety and induces conformational changes that allow dissociation of the co-repressor complex. On the other hand, PHF8 can be phosphorylated by CDK1. It dissociates from its naive chromatin-binding sites and is recruited by RARalpha fusions (illustrated by a big dashed red arrow). PHF8 removes the repressive H3K9me2 mark, but promotes active histone marks (H3K4 hypermethylation and K9 hyperacetylation) and recruitment of RNA polymerase II to turn on gene expression. Genes/proteins to be activated are bolded. Normal arrow indicates activation; blunted arrow indicates suppression; dashed arrow represents translocation of PHF8 protein; thickened arrows represent enhanced processes. 'me\' is hypermethylation; 'Ac\' is hyperacetylation; 'p\' is phosphorylation and '?\' indicates the mechanism remains unclear.](bjc2014374f1){#fig1}

![**Targeting ATRA-resistant APL.** In most of the cases, ATRA treatment induces degradation of RARalpha fusion and APL cell differentiation, resulting in complete remission. However, some APL patients are refractory to ATRA, or in some cases ATRA treatment may select/evolve drug-resistant clones that are no longer responsive to ATRA. Several approaches have been proposed to target ATRA-resistant APL. These include (1) retinoid derivatives with a higher affinity to the fusions; (2) ATO that binds to the PML moiety of the fusion and subsequently induces degradation of the onco-fusion; (3) HDACi that facilitate histone acetylation; and (4) overexpression or hyperphosphorylation of PHF8 that removes the repressive H3K9me2 mark to turn on the differentiation transcriptional programme.](bjc2014374f2){#fig2}
